Patents Assigned to Baylor
  • Biomarkers of recurrent infection
    Patent number: 10280470
    Abstract: Embodiments of the invention include methods and/or compositions for analysis of samples for C. difficile infection to determine whether or not an individual is at risk for having recurrent C. difficile infection or a CDI misdiagnosis. Methods include characterization of microflora composition from the gut, wherein alterations of the microflora gut composition are indicative of recurrence of infection. Methods include analysis of nucleic acids from the gut, such as 16S rRNA as being identifying of a particular bacteria in the analysis of bacterial populations of the gut.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: May 7, 2019
    Assignee: Baylor College of Medicine
    Inventors: Tor Savidge, Emily Hollister-Branton
  • Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacy
    Patent number: 10279009
    Abstract: Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: May 7, 2019
    Assignee: Baylor College of Medicine
    Inventors: Juan Fernando Vera Valdes, Malcolm Brenner, Usanarat Anurathapan
  • Ureteral stent and method
    Patent number: 10278806
    Abstract: The present disclosure provides a ureteral stent, having an elongated tube configured to be inserted into a ureter; a first end having a retainer portion configured to be inserted into a kidney; and a second end configured to be inserted into a bladder, the second end having an anchor portion fluidicly coupled with the first end, the second end having a collapsible wall expandable to a cross-sectional size greater than the cross-sectional size of the ureter; a tube port fluidicly coupled with the first end; and a flapper valve having at least two valve ends coupled to the anchor portion over the port; and a flexible middle portion between the at least two valve ends configured to flex toward the port to cover the port with a predetermined amount of ambient pressure in the bladder and flex away from the port when ambient pressure is lower than the predetermined amount.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: May 7, 2019
    Assignee: BAYLOR UNIVERSITY
    Inventors: Charles Wesley McMahon, Corrine Audrey Nief, Danielle Rae Schmidt, Lisa Jin Choe, Maria Guadalupe Aponte, Sara L. Pelayo
  • Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
    Patent number: 10279030
    Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: May 7, 2019
    Assignee: Baylor Research Institute
    Inventors: SangKon Oh, Dapeng Li
  • Reducing the proliferation of carcinoma cells by administration of a poly-oxygenated metal hydroxide
    Patent number: 10278988
    Abstract: A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O2) molecules. The carcinoma cells may comprise prostrate carcinoma (22Rv1). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: May 7, 2019
    Assignee: BAYLOR UNIVERSITY
    Inventors: Erica D. Bruce, John W. Woodmansee, Jr.
  • TROCARS
    Publication number: 20190125176
    Abstract: One aspect of the invention provides a trocar including: a central cylinder defining a central channel and having a distal end adapted and configured for insertion within a subject; one or more gas outlets located within the central cylinder proximate to the distal end of the trocar; and one or more liquid outlets located within the central cylinder on a proximal side of the one or more gas outlets. The one or more liquid outlets are adapted and configured to dispense a liquid when an endoscope is withdrawn from a fully extended position within the central channel of the trocar to a position proximate to the one or more liquid outlets. Distal advancement of the endoscope to a position adjacent to the one or more gas outlets removes liquid from a distal end of the endoscope.
    Type: Application
    Filed: April 13, 2017
    Publication date: May 2, 2019
    Applicants: Baylor College of Medicine, Texas Heart Institute
    Inventors: Bryan M. Burt, Mahmood Khan, William Cohn
  • Radiometric system and method for detecting ice accumulation inside an operating jet engine
    Patent number: 10274436
    Abstract: The present invention provides a system and method of detecting the presence of a foreign substance, such as ice, in an air-flow path within an operating jet engine by providing one or more electromagnetic sensors that are tuned to receive electromagnetic waves at one or more frequencies generated by the operating jet engine that change upon the presence of the foreign substance. In at least one embodiment, the waves can be transmitted to the electromagnetic sensor through an electromagnetically transparent window in a wall of the jet engine. In at least another embodiment, the electromagnetic sensor can be coupled with a connector that penetrates an operating chamber in the jet engine to measure the electromagnetic parameters of one or more components from within the chamber of the jet engine. In some embodiments, the amount of ice or other foreign substances can be measured or estimated.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 30, 2019
    Assignee: BAYLOR UNIVERSITY
    Inventors: Buford Randall Jean, Brandon Herrera, Stephen T. McClain
  • Small molecule regulators of steroid receptor coactivators and methods of use thereof
    Patent number: 10265315
    Abstract: Small molecule regulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing SRC-related diseases. The SRC-related diseases can include cancer, metabolic disorders, human immunodeficiency virus, neurodegenerative disorders, and/or inflammatory diseases. Also provided are methods for regulating SRC family proteins in a cell.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: April 23, 2019
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Bert W. O'Malley, David Michael Lonard, Jin Wang, Jianming Xu, Jianwei Chen
  • MiR-320e and colorectal cancer
    Patent number: 10260105
    Abstract: Embodiments provide methods and compositions related to determining treatments for colorectal cancer patients by detection and analysis of the expression level of miRNA such as miR-320e in the patients. Embodiments provide predictive, prognostic and/or diagnostics methods by identifying miRNAs that are useful for clinical management of cancer patients, particularly colorectal cancer patients or patients at risk or determined to have colorectal cancer. Methods and compositions are based, in part, on the discovery that expression of certain miRNAs in cancer patients is associated with advancing cancer stages and/or can predict the responsiveness of cancer therapy, and can, therefore, provide basis for designing treatment strategies. In particular embodiments, the miRNA molecule is miR-320, particularly miR-320e.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: April 16, 2019
    Assignee: Baylor Research Institute
    Inventors: Ajay Goel, Lucia Perez-Carbonell, C. Richard Boland
  • FIG4 gene mutations in neurodegeneration
    Patent number: 10260100
    Abstract: The present invention relates to neuropathy, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: April 16, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, BAYLOR COLLEGE OF MEDICINE
    Inventors: Miriam Meisler, James R. Lupski, Clement Chow
  • SHEATHS, METHODS OF USE, AND KITS INCLUDING THE SAME
    Publication number: 20190105470
    Abstract: One aspect of the invention provides a sheath including: a cylinder defining a central passage; a balloon located along an external surface of a distal end of the cylinder, the balloon lying substantially flush with or recessed from the external surface when deflated, but capable of projecting beyond the external surface when inflated; and an inflation port located at a proximal end of the cylinder, the inflation port in fluid communication with the balloon. Another aspect of the invention provides a kit including: a sheath as described herein and instructions for use.
    Type: Application
    Filed: April 6, 2017
    Publication date: April 11, 2019
    Applicant: Baylor College of Medicine
    Inventors: Naveen Yadav, Arun Rai, Christopher Graziano, Samit Soni, Richard Link
  • Therapeutics dispensing device and methods of making same
    Patent number: 10251778
    Abstract: A therapeutics delivery system, and methods of making and using same, are disclosed for environments that rapidly clear any injected therapeutics, such as a patient's eye. The therapeutics delivery system releases the drug in a therapeutically effective concentration for a desired duration of time with a predefined drug kinetics. In one embodiment, the embodiments of the present disclosure release a therapeutically effective concentration for a longer time period than other delivery systems, for instance from a day to a week. Certain embodiments comprise a therapeutics dispensing device comprising a biodissolvable hydrogel matrix for long term drug release that allows the device to be placed directly at the injured site, e.g., onto the surface at or near the injury, and retained there rather than through injection, whether locally or systematically.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: April 9, 2019
    Assignees: Baylor College of Medicine, REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ghanashyam Acharya, Stephen C. Pflugfelder, Cintia S. De Paiva, Jennifer L. Simpson
  • PLGA-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery
    Patent number: 10246560
    Abstract: Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some embodiments, also comprise 1-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-AP-MP-PLGA-PEI nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical research in cell cultures, animal models and plants.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Baylor College of Medicine
    Inventors: Jian-Ming Lu, Qizhi Yao, Changyi Chen
  • Potassium channel blockers and use thereof in the treatment of autoimmune diseases
    Patent number: 10246496
    Abstract: Novel analogues of the sea anemone Stichodactyla helianthus toxin ShK, and their use as, for example, therapeutic agents for treating autoimmune diseases are disclosed. The analogues comprise a ShK toxin polypeptide and an N-terminal extension comprising an amino acid sequence according to formula (I): wherein X?4 is D, E or other negatively-charged amino acid or derivative thereof, X?3 is E, I, L, S, V, W or a tryptophan derivative, X?2 is any amino acid, X?1 is any amino acid, a is absent or a first additional moiety, and b is absent or a second additional moiety.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: April 2, 2019
    Assignees: LA TROBE UNIVERSITY, MONASH UNIVERSITY, BAYLOR COLLEGE OF MEDICINE, PEPTIDES INTERNATIONAL, INC.
    Inventors: Raymond S. Norton, Shih Chieh Chang, Michael W. Pennington, Christine Beeton, Brian J. Smith
  • Diagnostic/prognostic marker and therapeutic target for cancer
    Patent number: 10227656
    Abstract: Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 12, 2019
    Assignee: Baylor College of Medicine
    Inventors: Bin He, Rainer B. Lanz, Nicholas Mitsiades, Qin Feng
  • IMMUNE STIMULATORY FUNCTION AND ANTI-TUMOR ACTIVITY OF TGF-ß PRIMED MYELOID DERIVED SUPPRESSOR CELLS (MDSC)
    Publication number: 20190046569
    Abstract: Embodiments of the disclosure concern methods and compositions related to cancer therapy using myeloid derived suppressor cells (MDSC) as a solo therapy or an adjunct therapy. The MDSCs are prepared by exposing bone marrow cells or blood cells to one or more compositions that induce their differentiation to MDSCs and also to TGF-?1, and in specific embodiments the exposure to TGF-?1 results in the MDSCs having anti-tumor activity and/or immune stimulatory activity.
    Type: Application
    Filed: September 14, 2016
    Publication date: February 14, 2019
    Applicant: Baylor College of Medicine
    Inventors: Andrew SIKORA, Padmini JAYARAMAN, Falguni PARIKH, Robin PARAHIR
  • Ulcerative colitis (UC)-associated colorectal neoplasia markers
    Patent number: 10190174
    Abstract: Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Baylor Research Institute
    Inventors: Ajay Goel, Yuji Toiyama, C. Richard Boland, Yoshinaga Okugawa
  • COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS
    Publication number: 20190010173
    Abstract: This present disclosure is directed to compound of Formula I and methods of using these compounds in the treatment of conditions in which modulation of a cathepsin, particularly cathepsin L, cathepsin K, and/or cathepsin B, will be therapeutically useful. Formula I: or a solvate or pharmaceutically acceptable salt thereof. Each of R1-R10 are independently selected from the group consisting of: hydrogen, alkoxy, halo, hydroxy, phosphate, phosphate salts, disodium phosphate, diphosphate dimer, diphosphate dimer salt, and sodium diphosphate dimer with at least one of R1-R10 is a phosphate or diphosphate dimer group.
    Type: Application
    Filed: August 12, 2016
    Publication date: January 10, 2019
    Applicants: Mateon Therapeutics, Inc., Baylor University
    Inventors: Kevin G. Pinney, Mary Lynn Trawick, Erica N. Parker, David J. Chaplin
  • CAPSULAR CLIP FOR CORRECTING ZONULAR WEAKNESS POST-CATARACT SURGERY
    Publication number: 20190000609
    Abstract: When zonular attachments of a capsule holding an implanted lens weaken after cataract surgery, a capsular clip may be utilized to secure the capsular bag to the eye wall. The capsular clip may comprise an eyelet and a flat hook. The hook may be inserted either via a small surgeon created separation between the anterior capsule leaflet and the intraocular lens or via puncturing the capsular bag in a small area, and may be placed between the capsular bag and the implanted lens to secure the capsule in the appropriate position within the eye. Suture thread may be fed through the eyelet of the capsular clip to sew the capsular clip to the eye wall, thus securing the capsular clip and the capsule in place.
    Type: Application
    Filed: December 15, 2016
    Publication date: January 3, 2019
    Applicant: Baylor College of Medicine
    Inventor: Marshall Bowes Hamill
  • Antagonistic anti-OX40L antibodies and methods of their use
    Patent number: 10167339
    Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: January 1, 2019
    Assignee: Baylor Research Institute
    Inventors: Yong-Jun Liu, Sandra Zurawski, SangKon Oh, Shino Hanabuchi, Haruyuki Fujita, Hideki Ueno, Patrick Blanco, Hyemee Joo